Association of the British Pharmaceutical Industry

Recent papers from Association of the British Pharmaceutical Industry

1. Reinvigorating the possibilities: Drug repurposing as a strategic access pathway for rare diseasesTranslational Science of Rare Diseases · 2026
2. Recommendations for the use of clinical outcome assessments in rare disease drug developmentEClinicalMedicine · 2026
3. Toward Standardized UV-C Exposure Methods for Polymeric Materials: Coordinated Multi-Laboratory Evaluation and Material ResponseStandards · 2026
4. Beyond data and technology: the need for new thinking to enable the era of precision preventionBMC Medicine · 2026
5. Medical device development and innovation for rare and pediatric populations: a global landscape overviewOrphanet Journal of Rare Diseases · 2026
6. Applying the international rare disease research consortium (IRDiRC) N-of-1 therapy task force eligibility criteria for individualised therapies use case: Duchenne muscular dystrophyNeuromuscular Disorders · 2025
7. From roadmap to a sustainable end-to-end individualized therapy pathwayTherapeutic Advances in Rare Disease · 2025
8. Drug–device combinations in rare diseases: Challenges and opportunitiesDrug Discovery Today · 2025
9. Personalized medicine: when the common becomes the rareFrontiers in Medicine · 2024
10. Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtableEClinicalMedicine · 2024
11. UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-MakingCancer Management and Research · 2024
12. Industry Perceptions and Experiences with the Access Consortium New Active Substance Work-Sharing Initiative (NASWSI): Survey Results and RecommendationsTherapeutic Innovation & Regulatory Science · 2024
13. Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLCJTO Clinical and Research Reports · 2024
14. Drug repurposing for rare: progress and opportunities for the rare disease communityFrontiers in Medicine · 2024
15. Medical Tourism and Egypt's Strategic Vision 2030: Pull Motivations That Trigger the International Patients' Intention to Visit Egypt as a Medical Tourism HubThe Academic Journal of Contemporary Commerical Research · 2022
16. Advancing UK Regulatory Science Strategy in the Context of Global Regulation: a Stakeholder SurveyTherapeutic Innovation & Regulatory Science · 2021
17. Does NICE influence the adoption and uptake of generics in the UK?The European Journal of Health Economics · 2020
18. Evaluating Associations Between Nonclinical Cardiovascular Functional Endpoints and Repeat-dose Cardiovascular Toxicity in the Beagle Dog: A Cross-company InitiativeToxicological Sciences · 2020
19. Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluationRegulatory Toxicology and Pharmacology · 2020
20. Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statementBritish Journal of Cancer · 2020